Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X?

Revolution Medicines (NASDAQ: RVMD) received full FDA approval for its once-daily pill Rasonque (daraxonrasib) to treat metastatic pancreatic cancer, describing it as “lightning-quick” versus the usual 10-month timeline under the CNPV program. The drug reportedly doubled survival in clinical testing and is supported by Phase 3 efficacy and a manageable safety profile; the stock has surged ~178% YTD versus ~13% for the S&P 500. RBC Capital Markets estimates could reach $28M in sales this quarter and $11.5B in annual worldwide sales, with additional label-expansion and an accelerated EU review already underway.

Analysis

The market is likely pricing a platform story, but the first monetization step is still a narrow, late-line oncology launch. That means the near-term driver is not peak sales but the slope of prescription adoption, payer coverage, and how quickly oncologists trust the tolerability profile in frail patients; if any of those lag, the post-approval multiple can compress even with a clean label.

The bigger second-order effect is competitive: this validates pan-RAS biology and raises the strategic value of broader mutation coverage versus single-mutation KRAS franchises. That is a medium-term threat to companies whose value depends on narrower pathway inhibition, but only if RVMD proves it can move earlier in therapy and into combinations without toxicity becoming the bottleneck. Until then, the real winners are the platform-adjacent assets and testing ecosystem, not the revenue line itself.

Contrarian view: consensus may be extrapolating a multi-billion-dollar global opportunity from a single approval event. The $11B+ framing depends on multiple successful label expansions, durable real-world benefit, and ex-US execution over 6-18 months; any one disappointment could re-rate the stock sharply. Falsifiers are simple: weak initial script/revenue run-rate over the next 1-2 quarters, adverse safety signal, or slower-than-expected EU/regional approvals.

Key Decisions for Investors

• Do not chase RVMD into the post-approval gap; wait for a 5-10% pullback or the first commercial-readout quarter before adding. Time horizon: 1-3 months. Risk/reward only improves once launch data replaces headline enthusiasm.
• For event-driven exposure, consider a small RVMD call spread 6-9 months out rather than outright stock if you want upside to label-expansion data with defined downside. The catalyst path is ex-US approvals and broader solid-tumor readouts, not the initial pancreatic launch.
• Relative-value idea: long RVMD / short XBI as a beta-hedged way to express platform validation while reducing sector drawdown risk. Use only if RVMD holds post-launch momentum and XBI remains range-bound; this should outperform over 3-6 months if the company executes.
• Watch AMGN and BMY as longer-dated competitive references, but do not short them yet; RVMD only becomes a real franchise threat if later-line data translate into earlier-line or combination use. Falsify the bull case if RVMD sales miss low expectations or payer access is slow.